InSightec Panel Acquiesces Despite Efficacy, Control Group Concerns

Labeling for InSightec's ExAblate 2000 non-invasive uterine fibroid treatment should describe "mitigations" to minimize the risk of nerve damage during the procedure, FDA advisory panel members recommend